Disease · HP_0100660
Dyskinesia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Dyskinesia. Diseases, record HP_0100660. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0100660
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Dyskinesia
- Open Targets ID
- HP_0100660
- Other names
- Disorder of involuntary muscle movements, Dyskinesis
- Highest stage of its drugs
- Phase 3, for 8 of its 23 drugs, from ClinicalTrials.gov and TTD
Source Open Targets
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LEVODOPA | CHEMBL1009 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| AMANTADINE | CHEMBL660 | Small molecule | Phase 3 | TTD | 5 | 4 | 4 | Drugs and targets |
| DEUTETRABENAZINE | CHEMBL3137326 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| AMANTADINE HYDROCHLORIDE | CHEMBL1569 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARBIDOPA | CHEMBL1200748 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVOBUPIVACAINE | CHEMBL1201193 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PARDOPRUNOX | CHEMBL2103832 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SUFENTANIL | CHEMBL658 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIPRAGLURANT | CHEMBL2346738 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 1 | 1 | Drugs and targets |
| MAVOGLURANT | CHEMBL3087515 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets61
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DRD3 | D(3) dopamine receptor | 3 | D2-like dopamine receptor agonist; Dopamine D3 receptor agonist; Dopamine receptors; D2 & D3 partial agonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| GRIN1 | Glutamate NMDA receptor; GRIN1/GRIN2B | 3 | Glutamate NMDA receptor; GRIN1/GRIN2B antagonist; Glutamate [NMDA] receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2B | Glutamate NMDA receptor; GRIN1/GRIN2B | 3 | Glutamate NMDA receptor; GRIN1/GRIN2B antagonist; Glutamate [NMDA] receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| DRD2 | D2-like dopamine receptor | 2 | D2-like dopamine receptor agonist; Dopamine receptors; D2 & D3 partial agonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GRIA1 | Glutamate receptor 1 | 2 | Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic, AMPA 1 antagonist | Phase 2 | https://conductscience.org/library/genes/2890 | Drugs and targets |
| GRIA2 | Glutamate receptor 2 | 2 | Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic, AMPA 2 antagonist | Phase 2 | https://conductscience.org/library/genes/2891 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2906 | Drugs and targets |
| GRIN3A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist | Phase 3 | https://conductscience.org/library/genes/116443 | Drugs and targets |
1 to 10 of 61
See all 61 targetsTrials30
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02153632 | Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID | Phase 3 | 135 | 2019-04-02 | Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | AMANTADINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02799381 | A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) | Phase 3 | 63 | 2020-08-18 | Parkinson's Disease (PD) | CARBIDOPA, LEVODOPA | Its record names the disease | ClinicalTrials.gov |
| NCT03813238 | A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents | Phase 3 | 63 | 2023-09-08 | Cerebral Palsy, Dyskinetic | DEUTETRABENAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT01789047 | Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease | Phase 2 | 42 | 2019-04-16 | Idiopathic Parkinson's Disease, Drug Induced Dyskinesia | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT00794313 | Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease | Not applicable | 3 | 2017-05-11 | Parkinson's Disease | AMANTADINE, TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT02162979 | Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease | Phase 2 | 2 | 2014-07-22 | Parkinson's Disease | SILDENAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT00406588 | SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations | Phase 3 | 295 | Advanced Stage Parkinson's Disease | LEVODOPA, PARDOPRUNOX | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00986414 | Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease | Phase 2 | 260 | Parkinson Disease, Dyskinesias | MAVOGLURANT | Its record names the disease | ClinicalTrials.gov | |
| NCT01538329 | Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease | Phase 2 | 210 | Parkinson Disease | AMANTADINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02264834 | Deambulatory Epidural During the Labour | Phase 3 | 164 | First Pregnancy | LEVOBUPIVACAINE, SUFENTANIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 30
See all 30 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| TEV-50717 vs Placebo: Number of Participants With Adverse Events (AEs) | 35 of 40 | 15 of 22 | 62 | NCT03813238 | Trial comparisons |
| TEV-50717 vs Placebo: deaths from any cause | 0 of 40 | 0 of 22 | 62 | NCT03813238 | Trial comparisons |
| TEV-50717 vs Placebo: serious adverse events | 0 of 40 | 0 of 22 | 62 | NCT03813238 | Trial comparisons |
| Levodopa-Carbidopa Intestinal Gel (LCIG) vs Optimized Medical Treatment (OMT): deaths from any cause | 0 of 28 | 0 of 33 | 61 | NCT02799381 | Trial comparisons |
| Levodopa-Carbidopa Intestinal Gel (LCIG) vs Optimized Medical Treatment (OMT): serious adverse events | 2 of 28 | 0 of 33 | 61 | NCT02799381 | Trial comparisons |
| TEV-50717 vs Placebo: Number of Participants With CGI-I Response | 6 of 31 | 4 of 21 | 52 | NCT03813238 | Trial comparisons |
| TEV-50717 vs Placebo: Number of Participants With CGI-S Response | 17 of 31 | 9 of 21 | 52 | NCT03813238 | Trial comparisons |
| TEV-50717 vs Placebo: Number of Participants With PGI-I Response | 18 of 31 | 9 of 20 | 51 | NCT03813238 | Trial comparisons |
| TEV-50717 vs Placebo: Number of Participants With CaGI-I Response | 8 of 31 | 4 of 20 | 51 | NCT03813238 | Trial comparisons |
| Topiramate vs Placebo (Sugar Pill): deaths from any cause | 0 of 21 | 0 of 21 | 42 | NCT01789047 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100660
GET https://conductscience.org/api/diseases/v1/HP_0100660/drugs?page=2